MISTI HEDGEPETH: Open Payments
NPI 1649753039 · MCCOMB, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,037 in 148 payments from 44 companies in 2025. Trend: 2023 $3,047 · 2024 $5,581 · 2025 $3,037
Food & beverage: $2,916Education: $121
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 9 | $319 |
| Janssen Biotech, Inc. | 14 | $279 |
| PFIZER INC. | 13 | $198 |
| AstraZeneca Pharmaceuticals LP | 7 | $173 |
| Celgene Corporation | 10 | $166 |
| Incyte Corporation | 8 | $138 |
| Aveo Pharmaceuticals, Inc. | 3 | $112 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $109 |
| ARRAY BIOPHARMA INC | 5 | $108 |
| Gilead Sciences, Inc. | 4 | $107 |
Products named: IBRANCE, KEYTRUDA, TALVEY, FOTIVDA, Trodelvy, TECVAYLI, Nubeqa, REBLOZYL.
Industry payments across MS — which companies pay providers there.
